Weekly round-up: Countdown to our Annual Healthcare Investor Conference has begun!
As it’s summer why not catch up on our latest videos counting down to our 16th Annual Healthcare Investor Conference, taking place on Thursday, 10th October 2024, at The King’s Fund in London.
You can watch speakers at the conference discuss the hot button topics in life science and look forward to the event on our Optimum TV.
Presented by Optimum’s own Stephen Adams, the latest episode features Dr Daniel Mahony, partner at Novo Holdings, and thought leader in the industry.
In this third episode Mahony talks about Novo Holdings’ £50m investment in Oxford Nanopore, and its third generation DNA sequencing technology.
“What attracted us is we think that it’s at a bit of an inflection point commercially, where it’s going to be able to start targeting markets using DNA sequencing technology that some of its competitors are going to struggle to get into,” Mahony said.
In Part 2, Geraldine O’Keefe, partner at EQT, discussed the life sciences market in 2024, noting the mood of cautious optimism among investors.
Kieran Murphy, chair of Gamma Biosciences, SPT Labtech, and Centiva, noted increased investment activity in Part 1.
Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on First-in-class ADC Drug Candidate Targeting Tissue Factor
Adcendo ApS and Multitude Therapeutics Inc. announced on Tuesday that they have signed a licensing agreement for the development of a novel, highly differentiated antibody-drug conjugate (ADC) targeting Tissue Factor (TF) with the development code ADCE-T02.
Adcendo will obtain the exclusive development and commercialization rights for the asset globally, except for the Greater China region where Multitude will retain development and commercialisation rights.
ADCE-T02 is a highly differentiated anti-TF ADC, and the first ADC with a Topoisomerase I inhibitor-based linker/payload, to enter into clinical development in Australia, US and Europe.
SoTF is a clinically validated ADC target that is highly expressed in indications such as non-small cell lung cancer, colorectal cancer, cervical cancer, oesophageal cancer, head and neck cancer, bladder cancer and certain gastrointestinal cancers, but its expression is limited in normal tissues.
The licensing agreement on ADCE-T02 expands Adcendo’s first-in-class ADC pipeline and allows Adcendo to become a clinical-stage biotech company in Q4 2024.
